Sandbox 645: Difference between revisions

Line 42:

1) Saquinavir (Invirase) is known to be one of the first FDA approved protease inhibitor for HIV treatment. This usually occurs by HIV protease binding an active site <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_tunnel/1'> tunnel tightly </scene>, which will prevent polyproteins from also binding. Saquniavir's chemical structure has the ability to <scene name='User:David_Canner/Sandbox_HIV/Hiv_morph2/9'> mimic the tetrahedral </scene> intermediate of the hydrolytic reaction to interact <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_cat/3'> strongly with the catalytic Asp residues</scene> <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_cat/3'> </scene>.

[[Image:Saquin1.gif|600px|thumb|center|Saquinavir mesylate is a white to off-white, very fine powder with an aqueous solubility of 2.22 mg/mL at 25°C.]]

Sandbox 645: Difference between revisions

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

Revision as of 08:55, 27 November 2012 view source Charles Short (talk \| contribs) 89 edits No edit summary ← Older edit		Revision as of 08:56, 27 November 2012 view source Charles Short (talk \| contribs) 89 edits No edit summary Newer edit →
Line 42:		Line 42:
	1) Saquinavir (Invirase) is known to be one of the first FDA approved protease inhibitor for HIV treatment. This usually occurs by HIV protease binding an active site <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_tunnel/1'> tunnel tightly </scene>, which will prevent polyproteins from also binding. Saquniavir's chemical structure has the ability to <scene name='User:David_Canner/Sandbox_HIV/Hiv_morph2/9'> mimic the tetrahedral </scene> intermediate of the hydrolytic reaction to interact <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_cat/3'> strongly with the catalytic Asp residues</scene> <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_cat/3'> </scene>.		1) Saquinavir (Invirase) is known to be one of the first FDA approved protease inhibitor for HIV treatment. This usually occurs by HIV protease binding an active site <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_tunnel/1'> tunnel tightly </scene>, which will prevent polyproteins from also binding. Saquniavir's chemical structure has the ability to <scene name='User:David_Canner/Sandbox_HIV/Hiv_morph2/9'> mimic the tetrahedral </scene> intermediate of the hydrolytic reaction to interact <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_cat/3'> strongly with the catalytic Asp residues</scene> <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_cat/3'> </scene>.
	[[Image:Saquin1.gif\|600px\|thumb\|center\|Saquinavir mesylate is a white to off-white, very fine powder with an aqueous solubility of 2.22 mg/mL at 25°C.]]		[[Image:Saquin1.gif\|600px\|thumb\|center\|Saquinavir mesylate is a white to off-white, very fine powder with an aqueous solubility of 2.22 mg/mL at 25°C.]]